I have spent my entire research career investigating cytomegalovirus (CMV). My training is in medical virology and I have committed considerable time to developing new laboratory assays and defining their performance in populations of humans. This led me to apply those methods to evaluate antiviral drugs and prototype vaccines against CMV in randomised controlled trials.
In performing this work I have mentored a series of trainees who have gone on to independent careers of their own in virology.
I consider my four most influential publications to be:
Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. The dynamics of human cytomegalovirus replication in vivo. Journal of Experimental Medicine (1999), 190,177-182.
Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral load to identify patients who develop cytomegalovirus disease after transplantation. Lancet (2000),355,2032-2036.
Griffiths PD, McLean A, Emery VC. Encouraging prospects for immunisation against primary cytomegalovirus. Vaccine (2001), 19, 1356-1362.
Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O’Beirne J, Thorburn D, Patch D, Atkinson CE, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Milne RSB, Emery VC, Burroughs AK. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet (2011), 377:1256-63.